Evidence map›Paper›PMID 24260137›Full record

Trial reportPloS one2013

Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009.

David B Hanna, Kate Buchacz, Kelly A Gebo, Nancy A Hessol, Michael A Horberg, Lisa P Jacobson, Gregory D Kirk, Mari M Kitahata, P Todd Korthuis, Richard D Moore and 14 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

David B HannaJohns Hopkins University, Baltimore, Maryland, United States of America ; Albert Einstein College of Medicine, Bronx, New York, United States of America.
Kate Buchacz
Kelly A Gebo
Nancy A Hessol
Michael A Horberg
Lisa P Jacobson
Gregory D Kirk
Mari M Kitahata
P Todd Korthuis
Richard D Moore
Sonia Napravnik
Pragna Patel
Michael J Silverberg
Timothy R Sterling
James H Willig
Ann Collier
Hasina Samji
Jennifer E Thorne
Keri N Althoff
Jeffrey N Martin
Benigno Rodriguez
Elizabeth A Stuart
Stephen J Gange
North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA)

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
NATURAL HISTORY OF AIDS IN HOMOSEXUAL MENU01AI035040 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DETELS, ROGER, MARTINEZ-MAZA, OTONIEL · 1993 to 2018
$75.2M
University of Pittsburgh Multicenter AIDS Cohort Study (MACS)U01AI035041 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MARTINSON, JEREMY JAMES, RINALDO, CHARLES R · 1993 to 2018
$71.4M
MULTICENTER AIDS COHORT STUDYU01AI035039 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WOLINSKY, STEVEN M · 1993 to 2018
$66.4M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
CIHR 169621CIHR CBR-86906CIHR CBR-94036CIHR HCP-97105CIHR KRS-86251CIHR TGF-96118NCI NIH HHS N02 CP055504NCI NIH HHS N02-CP55504NCRR NIH HHS M01 RR000052NCRR NIH HHS M01 RR000071NCRR NIH HHS M01 RR000079NCRR NIH HHS M01 RR000083NCRR NIH HHS M01-RR-00052NCRR NIH HHS M01-RR00071NCRR NIH HHS M01 RR000722NCRR NIH HHS M01-RR00079NCRR NIH HHS M01-RR00083NCRR NIH HHS M01-RR00722NCRR NIH HHS M01-RR025747NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1-RR024131NCRR NIH HHS UL1 RR025747NIAAA NIH HHS R01 AA016893NIAAA NIH HHS R01-AA16893NIAID NIH HHS K01 AI071725NIAID NIH HHS K01-AI071725NIAID NIH HHS K01 AI071754NIAID NIH HHS K01-AI071754NIAID NIH HHS K01 AI093197NIAID NIH HHS K01-AI093197NIAID NIH HHS K23-AI610320NIAID NIH HHS K24-AI1065298NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI036219NIAID NIH HHS P30-AI036219NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI054999NIAID NIH HHS P30-AI27757NIAID NIH HHS P30-AI27763NIAID NIH HHS P30-AI27767NIAID NIH HHS P30-AI50410NIAID NIH HHS P30-AI54999NIAID NIH HHS R24 AI067039NIAID NIH HHS R24-AI067039NIAID NIH HHS U01 AI031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI035039NIAID NIH HHS U01 AI035040NIAID NIH HHS U01 AI035041NIAID NIH HHS U01 AI035042NIAID NIH HHS U01 AI035043NIAID NIH HHS U01 AI037613NIAID NIH HHS U01 AI037984NIAID NIH HHS U01 AI042590NIAID NIH HHS U01 AI069918NIAID NIH HHS U01-AI069918NIAID NIH HHS U01-AI31834NIAID NIH HHS U01-AI34989NIAID NIH HHS U01-AI34993NIAID NIH HHS U01-AI34994NIAID NIH HHS U01-AI35004NIAID NIH HHS U01-AI35039NIAID NIH HHS U01-AI35040NIAID NIH HHS U01-AI35041NIAID NIH HHS U01-AI35042NIAID NIH HHS U01-AI35043NIAID NIH HHS U01-AI37613NIAID NIH HHS U01-AI37984NIAID NIH HHS U01-AI42590NICHD NIH HHS U01 HD032632NICHD NIH HHS U01-HD32632NIDA NIH HHS F31 DA030254NIDA NIH HHS F31-DA30254NIDA NIH HHS K24 DA000432NIDA NIH HHS K24-DA00432NIDA NIH HHS R01 DA004334NIDA NIH HHS R01 DA011602NIDA NIH HHS R01 DA012568NIDA NIH HHS R01-DA04334NIDA NIH HHS R01-DA11602NIDA NIH HHS R01-DA12568NIDA NIH HHS U01 DA036297NIMHD NIH HHS G12 MD007583PHS HHS AHQ290-01-0012PHS HHS CDC200-2006-18797
6 · The paper itself

Abstract

backgroundU.S. state AIDS Drug Assistance Programs (ADAPs) are federally funded to provide antiretroviral therapy (ART) as the payer of last resort to eligible persons with HIV infection. States differ regarding their financial contributions to and ways of implementing these programs, and it remains unclear how this interstate variability affects HIV treatment outcomes.

methodsWe analyzed data from HIV-infected individuals who were clinically-eligible for ART between 2001 and 2009 (i.e., a first reported CD4+ <350 cells/uL or AIDS-defining illness) from 14 U.S. cohorts of the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Using propensity score matching and Cox regression, we assessed ART initiation (within 6 months following eligibility) and virologic suppression (within 1 year) based on differences in two state ADAP features: the amount of state funding in annual ADAP budgets and the implementation of waiting lists. We performed an a priori subgroup analysis in persons with a history of injection drug use (IDU).

resultsAmong 8,874 persons, 56% initiated ART within six months following eligibility. Persons living in states with no additional state contribution to the ADAP budget initiated ART on a less timely basis (hazard ratio [HR] 0.73, 95% CI 0.60-0.88). Living in a state with an ADAP waiting list was not associated with less timely initiation (HR 1.12, 95% CI 0.87-1.45). Neither additional state contributions nor waiting lists were significantly associated with virologic suppression. Persons with an IDU history initiated ART on a less timely basis (HR 0.67, 95% CI 0.47-0.95).

conclusionsWe found that living in states that did not contribute additionally to the ADAP budget was associated with delayed ART initiation when treatment was clinically indicated. Given the changing healthcare environment, continued assessment of the role of ADAPs and their features that facilitate prompt treatment is needed.

Indexed as

Government ProgramsHealthcare FinancingAcquired Immunodeficiency SyndromeAnti-Retroviral AgentsCanadaFemaleHumansMaleRetrospective StudiesUnited StatesAnti-Retroviral Agents

Identifiers

PMID24260137
PMCPMC3832515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.